Home
/
Edesa Biotech, Inc.
/
Financials
/
Quarterly
Edesa Biotech, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Edesa Biotech, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2021
Jun 30, 2021
$0
Aug 13, 2021
Q2
2021
Mar 31, 2021
$0
May 14, 2021
Q1
2021
Dec 31, 2020
$0
Feb 16, 2021
Q3
2021
Jun 30, 2020
$110.0K
Aug 13, 2021
Q2
2021
Mar 31, 2020
$110.5K
May 14, 2021
Q1
2021
Dec 31, 2019
$107.8K
Feb 16, 2021
Q3
2020
Jun 30, 2019
$500
Aug 12, 2020
Q2
2019
Jun 30, 2019
$500
Aug 14, 2019
Q2
2020
Mar 31, 2019
$0
May 15, 2020
Q1
2020
Dec 31, 2018
$0
Feb 13, 2020
Q2
2019
Jun 30, 2018
$0
Aug 14, 2019
Q3
2018
Jun 30, 2018
$73.1K
Aug 8, 2018
Q2
2019
Mar 31, 2018
$64.1K
May 8, 2019
Q1
2019
Dec 31, 2017
$20.5K
Feb 5, 2019
Q3
2018
Jun 30, 2017
$20.5K
Aug 8, 2018
Q2
2018
Mar 31, 2017
$63.0K
May 7, 2018
Q1
2018
Dec 31, 2016
$141.9K
Feb 7, 2018
Q3
2017
Jun 30, 2016
$181.1K
Aug 9, 2017
Q2
2017
Mar 31, 2016
$326.3K
May 9, 2017
Q1
2017
Dec 31, 2015
$488.2K
Feb 6, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
($2.25M)
Feb 13, 2026
Q3
2025
Jun 30, 2025
($1.75M)
Aug 8, 2025
Q2
2025
Mar 31, 2025
($1.59M)
May 14, 2025
Q1
2026
Dec 31, 2024
($1.62M)
Feb 13, 2026
Q3
2025
Jun 30, 2024
($1.67M)
Aug 8, 2025
Q2
2025
Mar 31, 2024
($1.86M)
May 14, 2025
Q1
2025
Dec 31, 2023
($1.68M)
Feb 14, 2025
Q3
2024
Jun 30, 2023
($1.98M)
Aug 9, 2024
Q2
2024
Mar 31, 2023
($2.33M)
May 10, 2024
Q1
2024
Dec 31, 2022
($2.33M)
Feb 9, 2024
Q3
2023
Jun 30, 2022
($5.79M)
Aug 9, 2023
Q2
2023
Mar 31, 2022
($4.57M)
May 11, 2023
Q1
2023
Dec 31, 2021
($4.38M)
Feb 10, 2023
Q3
2022
Jun 30, 2021
($4.76M)
Aug 12, 2022
Q2
2022
Mar 31, 2021
($2.26M)
May 13, 2022
Q1
2022
Dec 31, 2020
($2.64M)
Feb 14, 2022
Q3
2021
Jun 30, 2020
($1.77M)
Aug 13, 2021
Q2
2021
Mar 31, 2020
($1.49M)
May 14, 2021
Q1
2021
Dec 31, 2019
($1.09M)
Feb 16, 2021
Q3
2020
Jun 30, 2019
($1.29M)
Aug 12, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
($2.34M)
Feb 13, 2026
Q3
2025
Jun 30, 2025
($1.90M)
Aug 8, 2025
Q2
2025
Mar 31, 2025
($1.64M)
May 14, 2025
Q1
2026
Dec 31, 2024
($1.90M)
Feb 13, 2026
Q3
2025
Jun 30, 2024
($1.93M)
Aug 8, 2025
Q2
2025
Mar 31, 2024
($2.22M)
May 14, 2025
Q1
2025
Dec 31, 2023
($1.86M)
Feb 14, 2025
Q3
2024
Jun 30, 2023
($2.06M)
Aug 9, 2024
Q2
2024
Mar 31, 2023
($2.41M)
May 10, 2024
Q1
2024
Dec 31, 2022
($2.38M)
Feb 9, 2024
Q3
2023
Jun 30, 2022
($5.80M)
Aug 9, 2023
Q2
2023
Mar 31, 2022
($4.58M)
May 11, 2023
Q1
2023
Dec 31, 2021
($5.16M)
Feb 10, 2023
Q3
2022
Jun 30, 2021
($6.07M)
Aug 12, 2022
Q2
2022
Mar 31, 2021
($9.51M)
May 13, 2022
Q1
2022
Dec 31, 2020
($2.61M)
Feb 14, 2022
Q3
2021
Jun 30, 2020
($1.77M)
Aug 13, 2021
Q2
2021
Mar 31, 2020
($1.52M)
May 14, 2021
Q1
2021
Dec 31, 2019
($1.11M)
Feb 16, 2021
Q3
2020
Jun 30, 2019
($1.32M)
Aug 12, 2020